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Abstract   
Background: Cortical grey matter (GM) lesions are common in multiple 
sclerosis (MS), but little is known about their temporal evolution. We 
investigated this in people with relapsing-remitting (RR) and secondary 
progressive (SP) MS. 
Methods: 27 people with RRMS, and 22 with SPMS were included in this 
study. Phase sensitive inversion recovery (PSIR) scans were acquired on two 
occasions. Cortical GM lesions were classified as intracortical (IC, only 
involving GM) and leucocortical (LC, mixed GM-white matter [WM]); WM 
lesions touching the cortex as juxtacortical (JC). On follow up scans, new IC, 
LC and JC lesions were identified, and any change in classification of lesions 
previously observed was noted. WM lesion counts in the whole brain were 
assessed on PD/T2-weighted scans. 
Results: Over a mean (SD) of 21.0 (5.8) months, the number of new IC 
lesions per person per year was greater in SPMS (1.6 [1.9]) than RRMS (0.8 
[1.9]) (Mann-Whitney p=0.039). All new LC lesions arose from previously 
seen IC lesions (SPMS 1.4 [1.8] per person per year, and RRMS 1.1 [1.0]), 
and none arose de novo or from previously seen JC lesions. Changes in 
cortical GM (either new IC or IC converting to LC) lesion counts did not 
correlate with the changes in WM lesion counts. 
Conclusions: New cortical GM lesions rarely arise from the WM and the rate 
of new IC lesion formation is not closely linked with WM lesion accrual. IC 
lesion formation appears to be more common in SPMS than RRMS. 
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Introduction 
 Histopathological [1-4] and magnetic resonance imaging (MRI) studies 
[5,6] have established that cortical grey matter (GM) lesions can be extensive 
and are clinically relevant in multiple sclerosis (MS). Cortical GM lesions are 
seen in all MS subtypes [1,2], but are particularly apparent in people with 
progressive MS [1,7]. Cortical lesions play a significant role in the 
accumulation of irreversible disability [5]. 
  
 Little is known about the development and evolution of cortical GM 
lesions [8-10]. It is uncertain whether lesions confined to cortical GM 
(intracortical [IC] lesions) accrue at the same rate as leucocortical (LC) lesions 
(those involving both GM and WM) or WM lesions, or whether the rate of 
cortical GM lesion formation is similar throughout the course of relapsing-
remitting (RR) and secondary progressive (SP) MS. It is also not known if LC 
lesions form de novo, or through the extension of IC lesions into WM, or 
juxtacortical (JC) WM lesions in to GM. Cortical GM demyelination has been 
linked with meningeal inflammation, providing a plausible mechanism for 
cortical GM lesion formation to occur independently of WM demyelination [11]. 
and so it cannot be assumed that an effect MS disease modifying treatments 
have on WM lesion accrual will be similar for GM lesions. 
 
 Investigating the evolution of cortical GM lesions in histopathological 
studies is not possible, as serial tissue sampling cannot be undertaken. 
Investigating lesion evolution in vivo with magnetic resonance imaging (MRI) 
has been hampered by limited detection of GM lesions using conventional 
scanning methods. However, with the development of MRI techniques that 
improve the detection of GM lesions, such as double inversion recovery  
[12,13] and more recently phase sensitive inversion recovery (PSIR) [14,15], it 
is now possible to see GM lesions in nearly everyone with MS. Compared 
with DIR, PSIR appears to increase GM lesion detection 2 to 3 times and, 
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importantly, allows cortical GM lesions to be more robustly distinguished from 
JC WM lesions, and sub-classified into IC and LC lesions [15,16]. Using a 
high resolution PSIR sequence, we studied the formation and evolution of 
cortical GM lesions on a lesion-by-lesion basis, and examined their 
relationship with WM lesion accrual. 
Methods  
 Sixty five people took part in this study; all gave a written informed 
consent. This study had approval from our local institutional ethics committee. 
Data from three people with RRMS had to be excluded due to MRI motion 
artefacts; of the remaining 62 people, 27 had RRMS, 22 SPMS, and 13 were 
healthy controls [See Table 1]. For the MS groups, a detailed clinical history 
was obtained and neurological examination undertaken. Disease duration, 
number of relapses since the baseline visit, and change in disease modifying 
therapy were all noted. Expanded disability status scale scores were 
estimated [17].  
 
 PSIR (0.5x0.5x2mm) and PD/T2-weighted (1x1x3mm) scans were 
acquired (as per our previous work [15]) on a 3T Philips Achieva system, on 
two occasions at least one year apart. Follow-up images were registered to 
baseline scans using NiftyReg (http://sourceforge.net/projects/niftyreg) [18] 
with an affine transformation. On baseline scans, cortical GM lesions were 
classified as IC or LC; WM lesions touching but not entering the cortex were 
classified as JC lesions. As in our previous work [15], a cortical GM lesion 
was defined as a focal hypointensity relative to the surrounding normal cortex, 
that involved the cortex in part or whole. When small or ill-defined on a single 
slice, a lesion was only counted if it was present on at least one other 
adjacent slice. If a lesion was only seen to involve cortical GM it was classified 
as being IC, and if it also involved WM it was classified as LC. Total cortical 
GM lesion counts were calculated as the sum of IC and LC lesion counts. On 
follow up scans, new cortical GM lesions were counted, and on a lesion-by-
lesion basis any change in classification of lesions previously identified in or 
adjacent to the cortex (e.g. from IC or JC to LC) was noted. The intra-operator 
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intra-class correlation coefficient, using this PSIR sequence and these criteria, 
was 0.995 for total cortical GM lesion counts (IC and LC), and for IC and LC 
lesions separately, 0.990 and 0.984 respectively [15]. The PD/T2-weighted 
scans were used to count new WM lesions appearing over the follow up 
interval. All lesion marking was undertaken by VS under the supervision of an 
experienced neuroradiologist (TY) using guidelines previously reported [15]. 
Marking of all scans was blind to clinical details.  
 
 Statistical analyses were performed using SPSS version 21 (SPSS, 
Chicago, IL, USA). Differences in demographic and clinical variables between 
RR and SPMS were examined using independent sample t-tests. Since lesion 
numbers tend not to be normally distributed, changes in lesion numbers were 
compared between patient groups using the Mann-Whitney test. Spearman 
rank correlation was used to investigate associations between GM and WM 
lesion accrual. The threshold for statistical significance was p≤0.05. 
Results 
The demographic and clinical details of the participants are shown in 
Table 1. As expected people with SPMS were older (mean 53.4 (SD 7.3) 
compared with 41.7 (10.9) years; p<0.001) and had longer disease durations 
than RRMS (25.4 (10.0) compared with 13.1 (9.5) years; p<0.001). The mean 
(SD) follow up period for the RR group was 22.2 (6.3) months and for SP 19.5 
(4.8) months, which was not significantly different. The median EDSS for 
people with RRMS was 1.0 at baseline (range 1.0-6.0) and 1.5 (range 1.0-6.0) 
at follow up, and for SPMS was 6.5 (range 4.0-8.5) at both time points. At 
baseline 23 RRMS and 9 of the SPMS group were on a disease modifying 
treatment, and during follow up disease modifying therapy was started in one 
person and changed in five people with RRMS. 
Baseline lesion characteristics 
Baseline and follow up lesion counts are given in Table 2. While the 
total number of cortical GM lesions (IC and LC combined) was higher in the 
SP compared with RRMS groups (46.6 [19.4] compared with 36.8 [14.8] 
respectively), this did not reach statistical significance. IC, LC and JC lesion 
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counts (Table 2) also did not differ significantly between the RR and SP 
groups. 
 
Lesion accrual 
At follow up the SPMS group had a statistically higher total number of cortical 
GM lesions when compared with the RRMS group (mean 49.0 (19.7) and 38.0 
(15.7) respectively; Mann-Whitney p=0.043), but again there was no 
statistically significant difference between the groups for IC, LC or JC lesion 
counts. All lesions seen at baseline remained visible at follow up. The accrual 
of new IC lesions per person per year was greater in SPMS (1.6 (1.9)) than 
RRMS (0.8 (1.9)) (Mann-Whitney p=0.039). No de novo new JC or LC lesions 
were seen, and new LC lesions were seen to evolve from IC lesions but not 
JC lesions (Table 2). An example of an IC lesion converting to LC, is shown in 
Figure 1. 
 
The mean number of lesions converting from IC (at baseline) to LC lesions (at 
follow up) per person per year was not significantly greater in SPMS than 
RRMS (1.4 [1.8] compared with 1.1 [1.0] respectively). No new cortical lesions 
were seen in controls. 
 
WM lesion accrual per year was not significantly different in RRMS and SPMS 
groups (Mean [SD]: 0.7 [1.3]) compared with 0.2 [0.4] respectively). No new 
WM lesions were seen in controls. In the entire MS group, there was no 
significant correlation between the number of new WM lesions and the 
number of lesions converting from IC to LC or the number of new IC lesions. 
Similar results were seen in the RRMS and SPMS subgroups, and so are not 
shown. 
Discussion  
The most striking finding in our study was that new LC lesions (lesions 
that involve both cortical GM and adjacent [JC] WM) evolved from pre-existing 
IC lesions (which are confined to GM), and not from JC WM lesions or de 
novo. We also found significantly more new IC lesions in SPMS than RRMS 
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and, consistent with previous work [10] we found that changes in IC lesion 
numbers did not correlate with changes in WM lesion counts. The latter 
finding suggests that cortical GM lesion accrual is not closely linked with WM 
lesion formation. 
 
In a previous study using DIR scans to identify and count cortical GM 
lesions, Calabrese and colleagues followed up a mixed cohort of people with 
MS over 6 years [5].When assessed at 3 years[10] , the average rate of new 
cortical lesions was ~0.6 per person per year in RRMS (n=76) and ~0.7 in 
SPMS (n=31). At 5 years [5], the new cortical GM lesion accrual was 0.6 per 
person per year in both RRMS (n=157) and SPMS (n=31), and the rate of 
new WM lesions was ~0.8 and ~0.3 per person per year in RRMS and SPMS 
groups respectively. At 6 years [10], in RRMS the mean rate of cortical lesion 
accrual was 0.9 per person per year (n=95), but SPMS figures were note 
reported. Roosendaal and colleagues also assessed cortical GM lesion 
formation in 13 people with RRMS (=9) and SPMS (n=4) over 3 years, but did 
not report on lesion accrual in these groups separately [9].  
 
In the present study, new cortical GM lesions formed at a rate of ~0.8 
in RRMS and ~1.6 per person per year in SPMS, and WM lesions at a rate of 
~0.7 and ~0.2 per person per year respectively. With the exception of new 
cortical GM lesion accrual in SPMS, our results are very similar to those of 
Calabrese et al. With regard to the rate of cortical GM lesion accumulation in 
SPMS, the discrepancy in results between studies may be due to chance 
alone. However, the SPMS group included in the present work also had a 
much longer mean disease duration (25.4 years compared with 11.6 years) 
and greater disability as measured by EDSS scores (median 6.5 compared 
with 4.5) than the previous study [5], and so these two studies may actually be 
looking different phases of progressive MS and it is possible that with longer 
disease duration there is an increase in formation of new IC lesions in SPMS. 
It is also possible that the difference reflects the use of different MRI 
sequences to detect cortical lesions in the studies (PSIR in ours and DIR in 
Calabrese et al.) 
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When we tracked individual lesions we found that LC lesions did not 
occur de novo, but instead arose from previously seen IC lesions, and the rate 
of conversion from IC to LC lesions was matched by the rate of new IC lesion 
formation.  As such, the apparently static total IC lesion counts (Table 2) gives 
a false impression of stability, when actually new IC lesions did occur (more 
so in SPMS), and other IC lesions extended into WM so increasing LC counts. 
This has important implications when assessing treatment effects, as counting 
either total IC or JC lesions alone may overlook substantial increases in the 
number of LC lesions and significantly underestimate the rate of new IC lesion 
formation. 
 
The total number of cortical GM lesions was significantly greater in the 
SPMS compared with RRMS group at follow-up. However, when we 
subdivided cortical GM lesions into IC and LC, while both lesion types were 
more numerous in SPMS compared with RRMS, and the difference was about 
twice as great for LC compared with IC lesions (Table 2), the differences did 
not reach statistical significance. We think that this relates to the size and 
heterogeneity of the cohorts, which while large enough to demonstrate a 
difference in total cortical GM lesion counts were too small to distinguish 
subtypes of cortical GM lesions. 
 
Consistent with previous work [10,19], we did not find a significant 
correlation between the formation of new cortical GM lesions and new WM 
lesions. There are a couple of possible explanations for this. First, that cortical 
GM and WM lesion genesis have at least partially different underlying 
mechanisms. As noted above, meningeal inflammation has been seen in 
tissue sample from people with SPMS, and linked with both the extent of 
cortical GM lesions [20], and the magnitude of neuronal loss [21], providing a 
plausible mechanism for GM lesions to form independently of WM lesions. 
Second, that similar mechanisms underlie both WM and GM lesion formation 
but have their greatest effect on WM and GM at different times. WM lesion 
accrual occurs most rapidly earlier in the clinical course of MS [10,22]. In 
contrast, the results of our study, and those from previous work [5], show that 
the rate of GM lesion formation is similar, if not higher, in SPMS compared 
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with RRMS. With improved discrimination between IC and LC lesions using 
the PSIR sequence [16], our study also suggests that new IC lesion formation 
is probably higher in SPMS than RRMS. 
 
In recent work, Rinaldi et al. [23] looked at the effects of natalizumab, 
interferons and glatiramer acetate, on the rate of IC lesion formation in people 
with RRMS. Over the two years of their study, the average number of new IC 
lesions per person per year was ~1.5 in the untreated group (n=35), ~0.7 in 
those taking interferon or glatiramer acetate (n=50) and ~0.1 in those 
receiving natalizumab. This demonstrates a potentially useful role for cortical 
GM lesion measures in treatment trials. Our results suggest that not only are 
new IC lesion counts of interest, but the expansion of IC lesions into LC may 
also provide additional information about treatment efficacy. 
 
A remaining limitation of our in vivo study is the sensitivity of cortical 
lesion detection on MRI. While using PSIR about 3 times more lesions IC are 
identified when compared with DIR [15], using DIR in vitro less than 10% of 
histopathologically confirmed IC lesions are detected [4]. It is therefore likely 
that many IC lesions are still not identified on the PSIR sequence. This is 
particularly the case for subpial lesions, which are the most common type of 
cortical GM lesion seen in histopathological studies [1], but are rarely seen on 
DIR or PSIR [12,15]. While this does not negate the results of the present 
study, it would be of great interest to know if the new IC lesions seen in this 
study began in a subpial location. It may be possible to address using ultra-
high field MRI: Recent work at 7T acquiring T2*-weighted scans has 
demonstrated that a substantial number of subpial lesions can be seen [24]. 
In addition, we registered the follow-up to baseline scans, which allowed us to 
more readily match lesions seen at baseline with those seen at follow-up. 
However, this registration step will have subtly blurred the follow-up images 
and so reduced contrast between lesions and surrounding tissues, and 
between GM and WM. Given that the contrast between GM lesions and 
normal-appearing GM is lower than that between WM lesions and normal-
appearing WM, and between GM and WM, slight blurring of the follow-up 
images will tend to make it relatively more difficult to detect IC lesions when 
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compared LC or JC lesions. As we only identified new IC, but no  new LC or 
new JC lesions, we do not think this can be explained by registration-
associated methodological bias, but we may have underestimated slightly the 
number of new IC lesions 
 
In conclusion, we have found that lesions that involve cortical GM 
rarely arise from the WM, the rate of cortical lesion formation in not closely 
linked with WM lesion accrual, and that new IC lesions probably arise more 
often in SPMS than RRMS. These results suggest that measuring WM lesion 
accrual alone is not a sufficient marker of MS disease activity and 
progression, and should encourage further efforts to develop MRI techniques 
that improve the in vivo detection of cortical lesions in MS.  
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Tables 
 
Table 1: Participant demographics 
Group Age (years) M:F Baseline 
EDSS 
Median 
(Range) 
Disease 
duration in 
years 
Scan interval in 
months 
Controls (n=13) 35.1 (12.2) 7 : 6 NA NA 24.6 (6.8) 
RRMS (n=27) 41.7 (11.0) 6 : 21 1.0 (1.0-6.0) 13.1 (9.5) 22.2 (6.3) 
SPMS (n=22) 53.4 (7.3) 9 : 13 6.5 (4.0-8.5) 25.4 (10.0) 19.5 (4.8) 
 
 
 
Mean (SD) shown unless noted otherwise; RRMS = relapsing remitting 
multiple sclerosis; SPMS = secondary progressive multiple sclerosis. 
 
Table 2: Number of cortical lesions seen at baseline and follow up 
Group 
Mean (standard deviation) lesion counts 
Baseline Follow up 
IC LC JC New IC IC to LC IC LC JC 
Controls 0.0 1.6 (2.6) 0.0 0.0 0.0 0.0 
1.6 
(2.6) 0.0 
RRMS 20.3 (9.9) 
16.4 
(12.0) 
7.7 
(9.3) 
1.1 
(2.0) 
1.7 
(1.5) 
19.7 
(10.2) 
18.2 
(12.2) 
7.6 
(9.2) 
SPMS 23.5 (10.6) 
23.1 
(15.3) 
11.6 
(12.5) 
2.4 
(2.6) 
2.1 
(1.9) 
23.8 
(10.6) 
25.2 
(16.0) 
11.6 
(12.5) 
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RRMS = relapsing remitting multiple sclerosis; SPMS = secondary 
progressive multiple sclerosis; IC = intracortical; LC = leucocortical; JC = 
juxtacortical. 
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Figures 
 
Figure 1: An intracortical lesion evolving into a leucocortical lesion 
 
 
Corresponding PSIR images at baseline (left) and follow up (right) showing an 
intracortical lesion at baseline that extends into white matter on follow up, so 
becoming a leucocortical lesion.
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